PMID- 18330505 OWN - NLM STAT- MEDLINE DCOM- 20081112 LR - 20181201 IS - 0300-8126 (Print) IS - 0300-8126 (Linking) VI - 36 IP - 2 DP - 2008 Mar TI - Influence of steroids on procalcitonin and C-reactive protein in patients with COPD and community-acquired pneumonia. PG - 163-6 LID - 10.1007/s15010-007-7206-5 [doi] AB - BACKGROUND: The induction of C-reactive Protein (CRP) may be attenuated by corticosteroids, whereas Procalcitonin (PCT) appears to be unaltered. We investigated, whether in community-acquired pneumonia (CAP) a combined antibiotic-corticosteroid therapy may actually lead to different slopes of decline of these inflammatory markers. PATIENTS AND METHODS: We studied the slopes of decline of PCT and CRP serum levels during 7 consecutive days as well as clinical parameters in a group of patients with CAP on or off corticosteroids. Patients with underlying COPD received systemic corticosteroids (n = 10), while non-COPD patients (n = 10) presenting with CAP alone formed the control group. All patients were treated with antibiotics. RESULTS: At baseline, relevant clinical and laboratory characteristics of the two groups were similar. Regarding the decreasing shapes of the curves from PCT and CRP, no significant differences were found (p-value = 0.48 for the groups for CRP, respectively 0.64 for PCT). All patients showed an uneventful recovery. CONCLUSION: In patients with COPD and CAP, the time courses over 7 days of PCT and CRP showed a nearly parallel decline compared to non-COPD patients with CAP. Contrary to the induction phase, corticosteroids do not modify the time-dependent decay of PCT and CRP when the underlying infectious disease (CAP) is adequately treated. FAU - Perren, A AU - Perren A AD - Intensive Care Unit, Ospedale Regionale Bellinzona e Valli, 6500, Bellinzona, Switzerland. andreas.perren@eoc.ch FAU - Cerutti, B AU - Cerutti B FAU - Lepori, M AU - Lepori M FAU - Senn, V AU - Senn V FAU - Capelli, B AU - Capelli B FAU - Duchini, F AU - Duchini F FAU - Domenighetti, G AU - Domenighetti G LA - eng PT - Clinical Trial PT - Journal Article PT - Multicenter Study DEP - 20080312 PL - Germany TA - Infection JT - Infection JID - 0365307 RN - 0 (Anti-Bacterial Agents) RN - 0 (Anti-Inflammatory Agents) RN - 0 (CALCA protein, human) RN - 0 (Protein Precursors) RN - 9007-12-9 (Calcitonin) RN - 9007-41-4 (C-Reactive Protein) RN - JHB2QIZ69Z (Calcitonin Gene-Related Peptide) RN - VB0R961HZT (Prednisone) RN - X4W7ZR7023 (Methylprednisolone) SB - IM MH - Aged MH - Anti-Bacterial Agents/therapeutic use MH - Anti-Inflammatory Agents/therapeutic use MH - C-Reactive Protein/*metabolism MH - Calcitonin/*blood MH - Calcitonin Gene-Related Peptide MH - Community-Acquired Infections/blood/complications/drug therapy MH - Drug Therapy, Combination MH - Female MH - Humans MH - Longitudinal Studies MH - Male MH - Methylprednisolone/*therapeutic use MH - Middle Aged MH - Pilot Projects MH - Pneumococcal Infections/drug therapy MH - Pneumonia/blood/complications/*drug therapy MH - Prednisone/*therapeutic use MH - Protein Precursors/*blood MH - Pulmonary Disease, Chronic Obstructive/blood/complications/*drug therapy EDAT- 2008/03/12 09:00 MHDA- 2008/11/13 09:00 CRDT- 2008/03/12 09:00 PHST- 2007/05/09 00:00 [received] PHST- 2007/09/19 00:00 [accepted] PHST- 2008/03/12 09:00 [pubmed] PHST- 2008/11/13 09:00 [medline] PHST- 2008/03/12 09:00 [entrez] AID - 10.1007/s15010-007-7206-5 [doi] PST - ppublish SO - Infection. 2008 Mar;36(2):163-6. doi: 10.1007/s15010-007-7206-5. Epub 2008 Mar 12.